Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12512352 | 0.89 | GPR119 (0.55) | GPR119USP30HTTSMN1; SMN2 | |
| SCHEMBL8657527 | 0.83 | SCD5 (0.53) | GPR119USP30HTT | |
| SCHEMBL12517353 | 0.83 | HTT (0.48) | GPR119USP30HTT | |
| SCHEMBL17151817 | 0.80 | GPR119 (0.53) | GPR119POLBSMN1; SMN2 | |
| SCHEMBL31247165 | 0.80 | KDM4E (0.52) | GPR119USP30HTT | |
| SCHEMBL3163929 | 0.80 | THRB (0.52) | GPR119USP30HTTSMN1; SMN2 | |
| SCHEMBL10099494 | 0.80 | HPGDS (0.54) | GPR119USP30 | |
| SCHEMBL4420449 | 0.80 | LMNA (0.61) | GPR119HTTPOLBSMN1; SMN2 | |
| SCHEMBL3767361 | 0.80 | ENPP2 (0.57) | GPR119USP30HTTPOLBSMN1; SMN2 | |
| SCHEMBL15824692 | 0.80 | HTT (0.51) | GPR119HTTPOLBSMN1; SMN2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | SCRIPPS RESEARCH INST (US) | 2026-02-19 | — | — | US | disclosed |
| WO-2024030121-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048047-A1 | SMALL-MOLECULE ACTIVATORS OF MYCOBACTERIUM TUBERCULOSIS ADENYLYL CYCLASE | FNTB, PDE7A, TBL3 | GPR119 471/4885USP30 4123/4885HTT 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.